Home

i følge konkurranse Lodge puma pharma Fortau skandale i går

Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet

Puma Biotechnology, Inc. 2018 Q3 - Results - Earnings Call Slides  (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. 2018 Q3 - Results - Earnings Call Slides (NASDAQ:PBYI) | Seeking Alpha

Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug  Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer |  Business Wire
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | Business Wire

Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha

Former Puma Biotech executive gets U.S. prison term for insider trading |  Reuters.com
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital |  citybiz
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz

Puma Biotechnology, Inc.
Puma Biotechnology, Inc.

Puma Biotechnology
Puma Biotechnology

Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On  Breast & Lung Cancer
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer

PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com

Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) |  Seeking Alpha
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital |  Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire

Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool

Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors  think so | Fierce Pharma
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma

Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection

Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit Outlook
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit Outlook

Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Announces $10 Million Private Placement | Business Wire

Puma Biotech punts near $300 million on Takeda discard
Puma Biotech punts near $300 million on Takeda discard

Puma Biotechnology | Evaluate
Puma Biotechnology | Evaluate

Puma Biotechnology: Finding Bullish Indications At The End Of 2019  (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer  Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in  China - Los Angeles Business Journal
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal

What Happened To Puma Biotechnology?
What Happened To Puma Biotechnology?

Articles with Puma Biotechnology
Articles with Puma Biotechnology

Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive  Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America